Citigroup Maintains Buy on ACADIA Pharmaceuticals, Lowers Price Target to $30.19
Portfolio Pulse from Benzinga Newsdesk
Citigroup analyst David Hoang has maintained a Buy rating on ACADIA Pharmaceuticals (NASDAQ:ACAD) but lowered the price target from $38 to $30.19.
March 12, 2024 | 6:04 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Citigroup maintains a Buy rating on ACADIA Pharmaceuticals but lowers the price target from $38 to $30.19.
While the maintenance of a Buy rating indicates continued confidence in ACADIA Pharmaceuticals' long-term prospects, the reduction in the price target could suggest a reassessment of near-term growth expectations or market conditions. This mixed signal might lead to short-term volatility in the stock price as investors digest the implications.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100